Mononitrosid (isosorbide Mononitrate) tablets 0.04 g. №40

$11.00

Purpose: Vasodilator, treats angina pectoris by dilating blood vessels.

SKU: MED59806 Category:

Description

Mononitrosid (Isosorbide Mononitrate) Tablets 0.04 g. №40

Ingredients

Active ingredient: Isosorbide Mononitrate 0.04 g per tablet.

Dosage

Dosage: The usual dose is 10-20 mg three times daily. Dosage may vary based on individual patient needs and response.

Indications

Indicated for: Prevention of angina pectoris due to coronary artery disease.

Contraindications

Contraindications: Hypersensitivity to nitrates, severe anemia, closed-angle glaucoma, hypotension.

Directions

– Take Mononitrosid tablets orally with a full glass of water.
– Do not crush or chew the tablets.
– Follow the dosage instructions provided by your healthcare provider.

Scientific Evidence

Isosorbide mononitrate, the active ingredient in Mononitrosid tablets, is a nitrate that works by dilating blood vessels, increasing blood flow, and reducing the workload on the heart. Studies have shown that isosorbide mononitrate is effective in preventing angina attacks and improving exercise tolerance in patients with coronary artery disease.

Additional Information

It is important to avoid sudden discontinuation of Mononitrosid tablets to prevent rebound angina. Consult your healthcare provider before starting or stopping this medication. Monitor blood pressure regularly while taking this medication.

Pharmacological Effects: Isosorbide mononitrate is a vasodilator that primarily affects veins, reducing the preload on the heart and decreasing myocardial oxygen demand. This leads to an improvement in symptoms of angina and an increase in exercise tolerance.

Clinical Trials: Clinical trials have demonstrated the efficacy of isosorbide mononitrate in reducing the frequency and severity of angina attacks. A study published in the Journal of the American College of Cardiology showed a significant decrease in the number of angina episodes and nitroglycerin usage in patients treated with isosorbide mononitrate compared to placebo.